TOHO HOLDINGS (8129) FY2026 Q3 Earnings Report

Quick View

Executive Summary

Although revenue increased and profits declined, net income rose sharply due to extraordinary gains, making the weakening profitability of the core business the primary point of focus. Revenue was ¥1,183.16B (+1.8% YoY), Operating Income was ¥12.42B (-13.3%), and Ordinary Income was ¥14.17B (-11.7%), while Net Income attributable to owners of the parent was ¥14.46B (+40.9%). The main reason for the decline in Operating Income was deteriorating profitability in the core pharmaceutical wholesale business, while the increase in Net Income was attributable to extraordinary gains of ¥6.81B, including a ¥4.81B gain on the sale of investment securities.

Factors Affecting Earnings

【Revenue】Revenue increased 1.8% YoY to ¥1,183.16B. The pharmaceutical wholesale business (93.1% of revenue composition) grew 1.6% YoY, while the dispensing pharmacy business grew 4.4% YoY, with both segments securing revenue growth. However, the growth rate remained below the full-year company plan of +3.5%.

【Profit and Loss】Operating Income declined 13.3% YoY to ¥12.42B, while Ordinary Income declined 11.7% to ¥14.17B. The gross margin was 7.7%, down approximately 30bp from the previous year, and the SG&A ratio of 6.7% was unable to absorb the decline, resulting in a decrease in the Operating Income margin to 1.0%. The primary reason for the decline was the lower profitability of the pharmaceutical wholesale business, which accounts for 85.9% of consolidated segment profit and recorded a 13.7% decline in profit. The gap between Ordinary Income and Net Income was substantial: Net Income of ¥14.46B was primarily attributable to extraordinary gains of ¥6.81B, including a ¥4.81B gain on the sale of investment securities and a ¥1.39B gain on the sale of fixed assets, rather than an improvement in the core business. In summary, this quarter’s results comprised higher revenue but lower profits, with the increase in Net Income attributable to temporary factors.

Segment Analysis

The pharmaceutical wholesale business recorded Revenue of ¥1,101.63B (+1.6% YoY) and segment profit of ¥12.31B (-13.7% YoY), with its profit margin declining from 1.27% in the previous year to 1.08%. The decline in this business, which accounts for the majority of consolidated profit, pushed down overall results. The dispensing pharmacy business achieved higher revenue and profit, with Revenue of ¥75.39B (+4.4% YoY) and segment profit of ¥1.18B (+60.6% YoY), while its profit margin improved from 1.02% to 1.56%. The pharmaceutical manufacturing and sales business recorded a substantial decline in segment profit to ¥0.17B (-69.2% YoY), with its profit margin declining from 6.27% to 1.91%. Other peripheral businesses recorded revenue growth of +11.2% YoY and profit growth of +32.7% YoY, with a profit margin of 12.84%, the highest among all businesses.

Key Financial Indicators

【Profitability】ROE was 5.4%, the Operating Income margin was 1.0% (down from 1.23% in the previous year), and the gross margin was 7.7% (down approximately 30bp from the previous year). The Net Income margin rose to 1.2% from approximately 0.88% in the previous year, primarily due to the boost from extraordinary gains. Under DuPont analysis, ROE of 5.4% comprises a Net Income margin of 1.2% × total asset turnover of 1.432x × financial leverage of 3.07x, reflecting a low-margin, high-turnover business structure. 【Cash Quality】Accounts receivable totaled ¥380.51B, representing 46.1% of total assets, and DSO was approximately 88 days, exceeding the general cautionary benchmark of 60 days, making management of the cash collection cycle important. Inventories totaled ¥98.64B, representing 11.9% of total assets. 【Investment Efficiency】Total asset turnover of 1.432x reflects the company’s large-scale commercial transactions. Goodwill was ¥0.11B and intangible fixed assets were ¥6.13B, together representing only 0.7% of total assets, indicating that M&A-related risk is limited. 【Financial Soundness】The Equity Ratio was 32.6%. Interest-bearing debt, comprising short-term debt, long-term debt, and bonds, totaled approximately ¥6.18B, while cash and deposits were substantial at ¥122.72B, indicating a financial position close to net cash. The current ratio was approximately 123.3% and the D/E ratio was approximately 2.07x, somewhat high; however, most liabilities comprised trade-related obligations such as accounts payable of ¥505.43B, and pressure arising from borrowings was limited.

Cash Flow Analysis

Although individual figures from the statement of cash flows are not included in the disclosed information, cash trends can be inferred from changes in the balance sheet. Cash and deposits increased substantially to ¥122.72B from ¥86.53B in the previous year, with cash inflows from the sale of investment securities and fixed assets considered one contributing factor. Accounts receivable totaled ¥380.51B and accounts payable totaled ¥505.43B, both increasing from the previous year, indicating an increase in working capital accompanying the expansion of business scale. Interest-bearing debt remained limited to approximately ¥7.65B, consisting of short-term borrowings of ¥1.65B, long-term borrowings of ¥4.25B, and bonds of ¥1.75B. Since cash and deposits substantially exceeded this amount, the company is considered to have ample financial flexibility in terms of funding and liquidity management.

Quality of Earnings

The quality of earnings for the current period requires careful interpretation due to the substantial gap between Ordinary Income and Net Income. Ordinary Income was ¥14.17B, while Net Income was ¥14.46B and included extraordinary gains of ¥6.81B, comprising a ¥4.81B gain on the sale of investment securities and a ¥1.39B gain on the sale of fixed assets. Non-operating income was ¥2.22B, primarily comprising dividend income of ¥0.86B, and remained limited at 0.19% of revenue. Extraordinary losses were small at ¥0.43B, including an ¥0.18B impairment loss on investment securities, resulting in net extraordinary gains of approximately ¥6.38B. Given that accounts receivable represent 46.1% of total assets, the high proportion of assets related to accruals warrants some attention regarding the speed of cash conversion from earnings. Overall, the key characteristic of the period was that the increase in Net Income was strongly dependent on the temporary factor of asset sales rather than an improvement in the recurring earnings power of the core business.

Earnings Forecast and Guidance

Progress against the full-year company forecast was broadly in line with the standard 75% level for Revenue at 75.3% (forecast: ¥1,572.0B), while Operating Income was 60.0% (forecast: ¥20.70B) and Ordinary Income was 62.7% (forecast: ¥22.60B), both 12–15 points below standard progress. Achieving the full-year Operating Income plan will require Operating Income of ¥8.28B in Q4, equivalent to approximately 66.7% of cumulative actual results, making an improvement in profitability a prerequisite. Meanwhile, progress toward Net Income attributable to owners of the parent was high at 92.0% (forecast: ¥15.70B), but this reflected extraordinary gains and does not indicate strong progress in recurring earnings power.

Shareholder Returns

The Q2 dividend was ¥45.00 per share, and the full-year dividend forecast is ¥120.00 per share. The Payout Ratio based solely on dividends, calculated using an estimated full-year total dividend payment of approximately ¥7.64B based on the average number of shares outstanding during the period, is approximately 48.6% against the full-year Net Income forecast of ¥15.70B. This Payout Ratio is within the generally sustainable range of less than 60%. However, because cumulative Net Income includes extraordinary gains, it is important to assess the sustainability of the dividend source by considering the recovery of Operating Income and Ordinary Income in the core business. No data on share repurchases was provided, and this section evaluates the Payout Ratio based solely on dividends.

Risk Factors

1. Deteriorating profitability in the core business: Segment profit in the pharmaceutical wholesale business declined 13.7% YoY, while its profit margin decreased by approximately 19bp. Under the low-margin structure represented by a gross margin of 7.7%, even small changes in pricing conditions, logistics expenses, and other factors can have a significant impact on consolidated profit.

2. Accounts receivable collection cycle: Accounts receivable totaled ¥380.51B, representing 46.1% of total assets, while DSO was approximately 88 days, exceeding the general cautionary benchmark of 60 days. Deterioration in the collection terms of business partners could affect working capital and the quality of revenue recognition.

3. Profit concentration in Q4: Achieving the full-year Operating Income plan requires Operating Income of ¥8.28B in Q4, equivalent to approximately 66.7% of cumulative Operating Income, making the generation of profit on this scale a prerequisite.

Industry Benchmark (For Reference; Company Research)

Profitability and Returns

Both the Company’s Operating Income margin and Net Income margin were below the industry median, placing the Company relatively low within the industry in terms of profitability.

Growth and Capital Efficiency

The Revenue growth rate was also below the industry median, indicating a relatively weak position within the industry in terms of growth.

※Source: Company research

Key Points in the Results

1. While Revenue is progressing in line with the plan, the full-year progress rates for Operating Income and Ordinary Income (60.0% and 62.7%) are below the standard 75% level. The extent to which profitability can be improved in the core pharmaceutical wholesale business will therefore be the focus going forward.

2. The high progress rate for Net Income (92.0%) is strongly dependent on extraordinary gains from the sale of investment securities and fixed assets, highlighting the structural need to evaluate it separately from the levels of Ordinary Income and Operating Income.

3. Interest-bearing debt is small at approximately ¥7.65B, substantially below cash and deposits of ¥122.72B. However, accounts receivable represent 46.1% of total assets and DSO is long at approximately 88 days. Accordingly, working capital management associated with commercial transactions, rather than borrowing costs, will be the key financial monitoring point.

Theoretical Share Price (Reference Value)

Sensitivity: ¥3,734–¥3,949 at Cost of Equity ±1%, and ¥3,829–¥3,846 at ω ±0.1.

Notes:

• Because progress toward full-year forecast Net Income (92%) exceeds the standard level (75%), Forecast EPS has been adjusted upward within a maximum range of +10% (because companies with progress ahead of forecast tend to outperform forecasts; the adjustment may be excessive for businesses with strong seasonality).
• Because forecast ROE is below the Cost of Equity, the theoretical value is below Book Value per Share.
• Net assets as of the end of the quarter are used (there is a timing difference from the full-year forecast).
• Because net assets include non-controlling interests, the theoretical value may be calculated somewhat high.

(Calculation model: Residual Income Model (Ohlson-type, explicit 5-year fade) / Interest rate reference month: 2026-07 / This is a mechanically calculated value based solely on publicly disclosed data and is not a forecast of the market share price or a recommendation of any specific investment action, nor does it predict or guarantee future share prices.)

---

This report is an earnings analysis document automatically generated by AI based on XBRL earnings summary data. It does not recommend investment in any specific security. The industry benchmarks are reference information compiled by the Company based on publicly disclosed earnings data. Investment decisions should be made at your own responsibility, after consulting professionals as necessary.

---End of Report---

---

AI Financial Analysis

Executive Summary

FY2026 Q3 performance was operationally weaker despite a sharp increase in reported net income, as securities and asset-sale gains more than offset a decline in core profitability. Revenue increased 1.8% year on year to ¥1,183.2bn. Operating income decreased 13.3% to ¥12.4bn, and ordinary income fell 11.7% to ¥14.2bn. The operating margin compressed by 18bp year on year to 1.05% from 1.23%. Gross margin declined by 11bp to 7.73%, indicating that modest top-line growth did not translate into improved gross-profit generation. SG&A increased 3.0%, faster than revenue growth, and the SG&A-to-sales ratio rose by 8bp to 6.69%. The pharmaceutical wholesale business remained the core earnings contributor but experienced a 13.7% decline in segment profit. In contrast, the dispensing pharmacy business delivered 60.6% segment-profit growth, partially cushioning wholesale weakness. Profit attributable to owners rose 40.9% to ¥14.4bn, but this was primarily supported by ¥6.8bn of extraordinary income. The largest extraordinary items were a ¥4.8bn gain on sales of investment securities and a ¥1.4bn gain on sales of fixed assets. Consequently, the 1.22% reported net margin is not representative of recurring operating profitability. Pre-tax income increased 28.6% to ¥20.5bn, while ordinary income declined, clearly illustrating the importance of non-recurring gains in the reported result. Annualized ROE was 7.2%, below the 8% threshold generally associated with an adequate return profile, though it was enhanced by financial leverage. Liquidity is adequate, with a 123.3% current ratio and a 104.7% quick ratio, while the balance sheet is supported by ¥122.7bn of cash against only ¥5.9bn of interest-bearing debt. The reported D/E ratio of 2.07x exceeds the 2.0x alert threshold, but this largely reflects substantial trade payables inherent in pharmaceutical distribution rather than funding debt; interest-bearing debt is only about 0.02x equity. The Q3 operating-income progress rate is only 60.0% of full-year guidance, 15.0 percentage points below the normal 75% Q3 pace, making a substantial Q4 earnings recovery necessary. Conversely, net-income progress is 92.0% of forecast, but this lead is largely attributable to asset-disposal gains and should not be extrapolated as recurring earnings momentum. The full-year ¥120 DPS forecast implies a dividend payout ratio of approximately 48.8% based on forecast EPS of ¥245.7, which appears supportable by forecast earnings.

Profitability Analysis

Annualized DuPont ROE is 7.2%, comprising a 1.2% net profit margin, 1.910x asset turnover, and 3.07x financial leverage. The key constraint is the structurally thin net margin rather than asset utilization: the company generates high turnover consistent with pharmaceutical wholesale distribution, but retains only a small share of revenue as profit. Financial leverage is the principal enhancer of ROE, with liabilities totaling 67.4% of assets, although most liabilities are operating payables rather than interest-bearing borrowings. The operating margin declined to 1.05% from 1.23%, a deterioration of 18bp. Gross margin fell to 7.73% from 7.84%, or by 11bp, while the SG&A ratio rose to 6.69% from 6.61%, or by 8bp. This combination explains the 13.3% reduction in operating income despite revenue growth. SG&A rose 3.0% to ¥79.1bn, exceeding the 1.8% revenue increase and demonstrating negative operating leverage over the nine-month period. Directors' compensation, the largest disclosed SG&A component, increased 2.6% to ¥35.2bn, while rent expense rose 2.6% to ¥6.1bn. Interest coverage remains exceptionally strong at 310.55x because interest expense was only ¥0.04bn, so financing cost is not a material drag on earnings. The five-factor DuPont interest-burden ratio of 1.654x is above 1.0x because extraordinary gains lifted profit before tax above EBIT; it should not be interpreted as an improvement in recurring debt-service economics. The tax burden was normal at 0.703, equivalent to a 29.6% effective tax rate. Under JGAAP, goodwill amortization was ¥0.82bn, but goodwill is only ¥1.11bn and therefore has no material impact on comparability or reported profitability.

Growth Assessment

Revenue growth of 1.8% was modest and principally led by the core pharmaceutical wholesale business, where external sales increased 1.6% to ¥1,101.6bn. The dispensing pharmacy business expanded faster, with revenue up 4.4% to ¥75.4bn. Pharmaceutical manufacturing and marketing revenue rose 2.0% to ¥2.0bn, while other peripheral businesses increased 11.2% to ¥4.1bn from a small base. Growth quality weakened at the consolidated operating level because gross-profit expansion was limited and SG&A grew faster than sales. The core wholesale segment generated ¥12.3bn of segment profit, down 13.7%, with a segment margin of approximately 1.08% on total segment sales. Dispensing pharmacy segment profit rose to ¥1.18bn from ¥0.73bn, with its margin improving to approximately 1.56% from 1.02%. Pharmaceutical manufacturing and marketing segment profit fell 69.2% to ¥0.17bn, reducing its margin to approximately 1.91% from 6.27%. Other peripheral businesses produced ¥0.68bn of segment profit, up 32.7%, and had the highest segment margin at approximately 12.84%, albeit on a small revenue base. The segment mix shows that pharmacy earnings are improving, but the scale of the wholesale segment means its margin trend remains the principal determinant of consolidated earnings. Full-year guidance assumes revenue of ¥1,572.0bn, implying Q3 revenue progress of 75.3%, broadly in line with the standard 75% pace. However, operating-income progress is only 60.0% versus the ¥20.7bn forecast, and ordinary-income progress is 62.7% versus the ¥22.6bn forecast. Achieving guidance therefore requires operating income of approximately ¥8.3bn in Q4, materially above the average quarterly run rate achieved during the first nine months. Net income has already reached 92.0% of the ¥15.7bn full-year forecast, but its apparent strength reflects the realized extraordinary gains rather than an equivalent improvement in underlying operations.

Financial Health

Liquidity is adequate but not excessive, with current assets of ¥653.8bn covering current liabilities of ¥530.3bn for a current ratio of 123.3%. The quick ratio is 104.7%, indicating that cash, receivables, and other near-liquid assets exceed current liabilities even before reliance on inventory liquidation. Working capital was positive at ¥123.5bn. The liability structure is dominated by accounts payable of ¥505.4bn, equivalent to 90.7% of total liabilities, which is consistent with a high-volume distribution model. Accounts payable increased 27.1% year on year to ¥505.4bn, materially faster than revenue growth, increasing reliance on supplier financing within ordinary operations. Cash and deposits increased 41.8% year on year to ¥122.7bn, strengthening immediate liquidity. Interest-bearing debt totaled only ¥5.9bn, comprising ¥1.7bn of short-term loans and ¥4.3bn of long-term loans, against cash of ¥122.7bn. Cash covered short-term loans by 74.19x, and interest coverage was 310.55x, indicating negligible refinancing and interest-payment pressure. Short-term debt represented 28.0% of interest-bearing debt, while current assets substantially exceeded this amount, so there is no material maturity mismatch from borrowing. A HIGH_LEVERAGE alert is triggered by the reported 2.07x D/E ratio, above the 2.0x threshold. Its root cause is the use of total liabilities relative to equity, particularly trade payables, rather than heavy financial borrowing. This balance-sheet structure is common for pharmaceutical wholesalers, where supplier payment obligations fund inventory and receivables, but the impact is that liquidity and working-capital discipline remain central to the risk profile. Equity increased 4.7% year on year to ¥268.9bn, but the equity ratio declined to 32.5% from 35.5% as total assets grew more rapidly. Goodwill decreased 42.5% to ¥0.11bn and is immaterial relative to assets and equity, leaving little M&A-related impairment exposure. Property, plant and equipment was ¥88.1bn, or 10.7% of total assets, while asset retirement obligations were ¥3.0bn.

Notable B/S Changes

Cash and deposits: +¥36.2bn (+41.8%) to ¥122.7bn - materially improves immediate liquidity and provides a substantial buffer against the ¥5.9bn interest-bearing debt balance. Accounts payable: +¥107.7bn (+27.1%) to ¥505.4bn - supplier-financing balance expanded far faster than revenue, reinforcing the need to monitor payment terms and working-capital sustainability. Goodwill: -¥0.8bn (-42.5%) to ¥0.1bn - goodwill is immaterial relative to equity and assets, so M&A-related impairment risk is limited.

Cash Flow Quality

Reported cash-flow figures are not available for the nine-month period, so cash conversion, operating-cash-flow-to-net-income, free cash flow, and dividend cash coverage cannot be quantified. Earnings-quality assessment can nevertheless be made from the income statement and working-capital balance sheet. Reported net income of ¥14.4bn exceeded operating income of ¥12.4bn because profit before tax included ¥6.8bn of extraordinary income, offset partly by ¥0.4bn of extraordinary losses. The ¥4.8bn gain on sales of investment securities and ¥1.4bn gain on sales of fixed assets are non-recurring realized gains and do not represent operating cash earnings from pharmaceutical distribution or pharmacy operations. Ordinary income of ¥14.2bn was also supported by ¥2.2bn of non-operating income, including ¥0.9bn of dividend income. Receivables were ¥380.5bn, or 46.1% of total assets, and the HIGH_RECEIVABLE_DAYS alert indicates DSO of 88 days, above the 60-day threshold. The root cause is the large credit exposure embedded in the distribution model, compounded by receivables increasing to ¥380.5bn from ¥332.5bn in the prior-year period. Such collection duration is common to some extent in wholesale distribution, but it raises the capital intensity of growth and makes cash conversion sensitive to payer collection timing. The impact is that revenue growth without tighter receivable control may not produce proportional operating cash flow. Inventory was ¥98.6bn, equal to 11.9% of assets, and increased 8.7% year on year, faster than revenue growth. Together, the receivables and inventory profile warrants monitoring for working-capital absorption, particularly because operating margins are only around 1%.

Dividend Sustainability

The company paid an interim Q2 dividend of ¥45 per share and forecasts a full-year dividend of ¥120 per share. Based on forecast EPS of ¥245.7, the forecast dividend payout ratio is approximately 48.8%, below the 60% sustainability benchmark. The disclosed Q2 payout ratio was 22.7% based on the ¥45 interim dividend and nine-month profit. The implied remaining year-end dividend is ¥75 per share if the full-year forecast is maintained. Forecast earnings of ¥15.7bn would cover the full-year dividend commitment of approximately ¥7.6bn using the 63.64 million average shares, leaving room for retained capital. Balance-sheet liquidity also supports distributions, with ¥122.7bn of cash and only ¥5.9bn of interest-bearing debt. However, dividend sustainability should be assessed against recurring profitability rather than the Q3 net-income outperformance, since gains on securities and asset disposals contributed materially to the nine-month result. The principal condition for maintaining the forecast distribution is delivery of the required Q4 recovery in operating profit and continued working-capital discipline. No share-buyback amount is available, so a total return ratio cannot be calculated.

Risk Assessment

Business risks include Pharmaceutical wholesale profitability risk: the core wholesale segment's profit declined 13.7% to ¥12.3bn despite 1.6% revenue growth, demonstrating high sensitivity to small changes in gross margin and distribution costs., LOW_OPERATING_EFFICIENCY alert: EBIT margin of 1.1% is below the 5% concern threshold. The root cause is a 7.7% gross margin largely absorbed by a 6.7% SG&A ratio. This is structurally consistent with wholesale distribution, but it leaves limited earnings protection against price pressure, logistics inflation, labor costs, or reimbursement-related changes., LOW_GROSS_MARGIN alert: the 7.7% gross margin is below the stated 20% benchmark. The benchmark is not directly comparable with pharmaceutical distribution, where high turnover and low margins are normal, but the year-on-year 11bp decline is material given the narrow profit pool., Pharmacy earnings improved strongly, but its ¥1.18bn segment profit remains too small to fully offset earnings pressure in the ¥12.3bn wholesale segment., Receivables-collection risk: DSO of 88 days and receivables of ¥380.5bn create exposure to delayed collections and ongoing working-capital funding needs., Industry-specific risk: pharmaceutical pricing revisions, generic-drug mix changes, wholesaler competition, and regulatory reimbursement policy can compress already thin distribution margins..

Financial risks include HIGH_LEVERAGE alert: reported D/E of 2.07x exceeds 2.0x, reflecting the large trade-payable base. Although interest-bearing debt is low and interest coverage is strong, the company depends on efficient settlement of supplier payables and customer receivables., Accounts payable increased 27.1% year on year to ¥505.4bn, far faster than revenue growth. This supports working capital in the near term but increases sensitivity to payment terms and supplier-credit conditions., The equity ratio declined to 32.5% from 35.5% as assets and liabilities expanded faster than equity, reducing the balance-sheet buffer modestly., Reported net income is exposed to investment-security and fixed-asset disposal gains; the absence of similar gains would leave profit more closely aligned with the weaker ordinary-income trend..

Key concerns include Highest priority: a Q4 operating-income recovery of approximately ¥8.3bn is required to meet full-year guidance, versus ¥12.4bn generated cumulatively in the first nine months., High priority: monitor wholesale gross margin, SG&A intensity, receivable days, inventories, and accounts-payable growth because small working-capital or margin movements can have disproportionate effects on cash generation and earnings., Moderate priority: the strong net-income progress rate is not an indicator of recurring earnings strength because extraordinary gains totaled ¥6.8bn., Moderate priority: low goodwill and low interest-bearing debt reduce acquisition-related impairment and refinancing risks..

Investment Implications

Key takeaways include Core earnings weakened: revenue increased 1.8%, but operating income declined 13.3% and operating margin fell 18bp to 1.05%., Reported net-income growth of 40.9% was driven primarily by ¥6.8bn of extraordinary income, notably investment-security and fixed-asset sales., The wholesale business remains the core business, contributing ¥12.3bn of segment profit, but its profit decline is the main issue for consolidated earnings., The dispensing pharmacy business provides a positive offset, with segment profit rising 60.6% to ¥1.18bn., Liquidity and debt service capacity are strong due to ¥122.7bn of cash, minimal ¥5.9bn interest-bearing debt, and 310.55x interest coverage., Full-year operating guidance requires a meaningful Q4 acceleration, while net-income forecast progress is flattered by non-recurring gains..

Metrics to watch include Wholesale segment profit and segment margin, Consolidated gross margin and SG&A-to-sales ratio, Q4 operating income relative to the approximately ¥8.3bn required to achieve full-year guidance, DSO, accounts receivable, inventory growth, and accounts payable settlement trends, Recurring ordinary income excluding securities and fixed-asset disposal gains, Full-year dividend execution relative to the ¥120 per share forecast.

Regarding relative positioning, The company exhibits the high-turnover, low-margin and trade-payables-funded profile typical of a pharmaceutical wholesaler. Its liquidity and interest-bearing debt position are stronger than the headline D/E ratio alone implies, but annualized ROE of 7.2% and an EBIT margin of 1.1% indicate limited profitability headroom. The improving pharmacy segment is strategically constructive, while the scale and margin trajectory of wholesale operations remain the dominant determinant of relative earnings quality.